Helen M. Thackray
CIK 1589725 · Chief R&D Officer · last filed 2025-04-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.28M
Companies
3
Total Filings
38
Lifetime Open-Market Net
-$348.8K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCRX | Chief R&D Officer | 377,318 | $8.70 | $3.28M | -$39.4K | 15 | 2025-04-02 |
| ImmunoGen, Inc. (IMGN) Delisted | Director | 0 | $31.23 | $0 | $0 | 8 | 2024-02-12 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | SVP Clinical Development, CMO | 183,115 | $15.70 | $2.87M | -$309.4K | 15 | 2021-01-22 |
Recent Filings · Page 3 of 4
38 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-02 | BCRX | Grant (A) | +100,000 | $0 | EDGAR |
| 2021-01-22 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +34,500 | $0 | EDGAR |
| 2020-05-14 | BCRX | Grant (A) | — | $0 | EDGAR |
| 2020-01-24 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-09-24 | BCRX | Grant (A) | — | $0 | EDGAR |
| 2019-01-22 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-12 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-12 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Sell (S) | −2,000 | -$30.0K | EDGAR |
| 2017-09-18 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Sell (S) | −2,000 | -$26.0K | EDGAR |
| 2017-05-30 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Sell (S) | −2,000 | -$31.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.